Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor and Lymphoma Malignancies 1Advanced Solid Neoplasms 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × TAK-659 × Clear all
NCT03238651 2023-02-08

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Calithera Biosciences, Inc

Phase 1 Terminated
17 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT03359733 2023-02-08

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡